Co-treatment with Gabapentinoid and Japanese Herbal Medicine Goshajinkigan for CIPN is Associated with Longer Duration and Higher Dose of Chemotherapy

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-04-19 DOI:10.1007/s12325-025-03173-z

Kanako Miyano, Yasuhito Uezono, Takuhiro Yamaguchi, Wataru Hashimoto, Satoshi Komoriya

{"title":"Co-treatment with Gabapentinoid and Japanese Herbal Medicine Goshajinkigan for CIPN is Associated with Longer Duration and Higher Dose of Chemotherapy","authors":"Kanako Miyano, Yasuhito Uezono, Takuhiro Yamaguchi, Wataru Hashimoto, Satoshi Komoriya","doi":"10.1007/s12325-025-03173-z","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>In Japan, both gabapentinoids and the Japanese traditional herbal medicine goshajinkigan (GJG) are used to manage chemotherapy-induced peripheral neuropathy (CIPN); however, evidence for their effectiveness is inconclusive. Patients with CIPN experience reduced quality of life and often undergo reductions in dose or discontinuation of chemotherapy. Therefore, this retrospective cohort study used a real-world database to examine the efficacy of gabapentinoids and GJG therapy for patients with CIPN by evaluating chemotherapy duration and dose.</p><h3>Methods</h3><p>Data from 145,384 patients diagnosed with CIPN while receiving platinum- or taxane-based chemotherapy between April 1, 2008 and March 31, 2022 were stratified by CIPN treatment: simultaneous gabapentinoid (mirogabalin or pregabalin) plus GJG (prescription dates overlap); non-simultaneous gabapentinoid plus GJG (prescription dates do not overlap); gabapentinoid alone; GJG alone; and neither gabapentinoids nor GJG. Duration and dose of chemotherapy were the primary outcomes.</p><h3>Results</h3><p>Treatment with either a gabapentinoid or GJG alone was associated with longer duration and higher doses of chemotherapy versus neither gabapentinoids nor GJG in patients treated with carboplatin, cisplatin, or paclitaxel. Combined gabapentinoid plus GJG treatment elicited further longer duration and higher doses of chemotherapy versus gabapentinoid alone or GJG alone in patients treated with carboplatin, oxaliplatin, cisplatin, paclitaxel, or docetaxel. When stratified by cancer type, similar trends were observed regarding combination gabapentinoid plus GJG treatment among patients with colorectal cancer treated with oxaliplatin and patients with gastric, lung, or breast cancer treated with paclitaxel.</p><h3>Conclusion</h3><p>Combination treatment with gabapentinoid plus GJG might prevent reductions in dose or discontinuation of chemotherapy, and might be effective for the treatment of CIPN.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2833 - 2852"},"PeriodicalIF":3.4000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03173-z.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03173-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

In Japan, both gabapentinoids and the Japanese traditional herbal medicine goshajinkigan (GJG) are used to manage chemotherapy-induced peripheral neuropathy (CIPN); however, evidence for their effectiveness is inconclusive. Patients with CIPN experience reduced quality of life and often undergo reductions in dose or discontinuation of chemotherapy. Therefore, this retrospective cohort study used a real-world database to examine the efficacy of gabapentinoids and GJG therapy for patients with CIPN by evaluating chemotherapy duration and dose.

Methods

Data from 145,384 patients diagnosed with CIPN while receiving platinum- or taxane-based chemotherapy between April 1, 2008 and March 31, 2022 were stratified by CIPN treatment: simultaneous gabapentinoid (mirogabalin or pregabalin) plus GJG (prescription dates overlap); non-simultaneous gabapentinoid plus GJG (prescription dates do not overlap); gabapentinoid alone; GJG alone; and neither gabapentinoids nor GJG. Duration and dose of chemotherapy were the primary outcomes.

Results

Treatment with either a gabapentinoid or GJG alone was associated with longer duration and higher doses of chemotherapy versus neither gabapentinoids nor GJG in patients treated with carboplatin, cisplatin, or paclitaxel. Combined gabapentinoid plus GJG treatment elicited further longer duration and higher doses of chemotherapy versus gabapentinoid alone or GJG alone in patients treated with carboplatin, oxaliplatin, cisplatin, paclitaxel, or docetaxel. When stratified by cancer type, similar trends were observed regarding combination gabapentinoid plus GJG treatment among patients with colorectal cancer treated with oxaliplatin and patients with gastric, lung, or breast cancer treated with paclitaxel.

Conclusion

Combination treatment with gabapentinoid plus GJG might prevent reductions in dose or discontinuation of chemotherapy, and might be effective for the treatment of CIPN.

查看原文本刊更多论文

加巴喷丁类与日本中草药Goshajinkigan联合治疗CIPN患者化疗时间更长、剂量更高。

简介：在日本，加巴喷丁类药物和日本传统草药goshajinkigan （GJG）被用于治疗化疗引起的周围神经病变（CIPN）；然而，其有效性的证据尚无定论。CIPN患者的生活质量下降，经常需要减少化疗剂量或停止化疗。因此，本回顾性队列研究使用真实世界的数据库，通过评估化疗时间和剂量来检验加巴喷丁类药物和GJG治疗CIPN患者的疗效。方法：2008年4月1日至2022年3月31日期间，145,384名在接受铂类或紫杉烷类化疗时被诊断为CIPN的患者的数据按CIPN治疗进行分层：加巴喷丁类（米罗巴林或普瑞巴林）加GJG（处方日期重叠）；非同时加巴喷丁类加GJG（处方日期不重叠）；单独类;GJG孤独;加巴喷丁素和GJG都没有。化疗时间和剂量是主要结局。结果：在卡铂、顺铂或紫杉醇治疗的患者中，加巴喷丁类药物或GJG单独治疗与加巴喷丁类药物或GJG治疗相比，化疗持续时间更长，剂量更高。在卡铂、奥沙利铂、顺铂、紫杉醇或多西紫杉醇治疗的患者中，加巴喷丁类加GJG联合治疗比加巴喷丁类单独治疗或GJG单独治疗的持续时间更长，化疗剂量更高。当按癌症类型分层时，在使用奥沙利铂治疗的结直肠癌患者和使用紫杉醇治疗的胃癌、肺癌或乳腺癌患者中，观察到加巴喷丁类加GJG联合治疗的类似趋势。结论：加巴喷丁类药物联合GJG治疗CIPN可预防剂量减少或停药，可能是治疗CIPN的有效方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.